| 1. | Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021, 71(3): 209-249. | 
				                                                        
				                                                            
				                                                                | 2. | Garcia-Monaco RD, Chung JW, Vilgrain V, et al. Summary of key guidelines for locoregional treatment of HCC in Asia, Europe, South and North America. Br J Radiol, 2022, 95(1138): 20220179. doi: 10.1259/bjr.20220179. | 
				                                                        
				                                                            
				                                                                | 3. | Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology, 2018, 68(2): 723-750. | 
				                                                        
				                                                            
				                                                                | 4. | Dimitroulis D, Damaskos C, Valsami S, et al. From diagnosis to treatment of hepatocellular carcinoma: an epidemic problem for both developed and developing world. World J Gastroenterol, 2017, 23(29): 5282-5294. | 
				                                                        
				                                                            
				                                                                | 5. | Wang Q, Zhao P, He N, et al. Combination of the gamma-glutamyltransferase-to-prealbumin ratio and other indicators may be a novel marker for predicting the prognosis of patients with hepatocellular carcinoma undergoing locoregional ablative therapies. Infect Agent Cancer, 2019, 14: 49. doi: 10.1186/s13027-019-0266-1. | 
				                                                        
				                                                            
				                                                                | 6. | Ke Q, Xiang F, Xiao C, et al. Exploring the clinical value of preoperative serum gamma-glutamyl transferase levels in the management of patients with hepatocellular carcinoma receiving postoperative adjuvant transarterial chemoembolization. BMC Cancer, 2021, 21(1): 1117. doi: 10.1186/s12885-021-08843-z. | 
				                                                        
				                                                            
				                                                                | 7. | Huo RR, Liu HT, Deng ZJ, et al. Dose-response between serum prealbumin and all-cause mortality after hepatectomy in patients with hepatocellular carcinoma. Front Oncol, 2021, 10: 596691. doi: 10.3389/fonc.2020.596691. | 
				                                                        
				                                                            
				                                                                | 8. | Liang L, Quan B, Wu H, et al. Development and validation of an individualized prediction calculator of postoperative mortality within 6 months after surgical resection for hepatocellular carcinoma: an international multicenter study. Hepatol Int, 2021, 15(2): 459-471. | 
				                                                        
				                                                            
				                                                                | 9. | Nakayama H, Okamura Y, Higaki T, et al. Effect of blood product transfusion on the prognosis of patients undergoing hepatectomy for hepatocellular carcinoma: a propensity score matching analysis. J Gastroenterol, 2023, 58(2): 171-181. | 
				                                                        
				                                                            
				                                                                | 10. | 俞巍, 張洪義, 王鵬輝. 射頻消融治療肝癌的研究進展. 中國臨床醫生雜志, 2021, 49(4): 385-387. | 
				                                                        
				                                                            
				                                                                | 11. | Liu Y, Liu L. Changes in the epidemiology of hepatocellular carcinoma in Asia. Cancers (Basel), 2022, 14(18): 4473. doi: 10.3390/cancers14184473. | 
				                                                        
				                                                            
				                                                                | 12. | Ren A, Li Z, Zhang X, et al. Inflammation-based prognostic scores in patients with hepatitis B virus-related hepatocellular carcinoma after liver transplantation. J Hepatocell Carcinoma, 2020, 7: 101-106. | 
				                                                        
				                                                            
				                                                                | 13. | Zhang LX, Lv Y, Xu AM, et al. The prognostic significance of serum gamma-glutamyltransferase levels and AST/ALT in primary hepatic carcinoma. BMC Cancer, 2019, 19(1): 841. doi: 10.1186/s12885-019-6011-8. | 
				                                                        
				                                                            
				                                                                | 14. | Corti A, Franzini M, Paolicchi A, et al. Gamma-glutamyltransferase of cancer cells at the crossroads of tumor progression, drug resistance and drug targeting. Anticancer Res, 2010, 30(4): 1169-1181. | 
				                                                        
				                                                            
				                                                                | 15. | Fan Y, Sun Y, Man C, et al. Preoperative serum prealbumin level and adverse prognosis in patients with hepatocellular carcinoma after hepatectomy: a meta-analysis. Front Oncol, 2021, 11: 775425. doi: 10.3389/fonc.2021.775425. | 
				                                                        
				                                                            
				                                                                | 16. | Johnson P, Zhou Q, Dao DY, et al. Circulating biomarkers in the diagnosis and management of hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol, 2022, 19(10): 670-681. | 
				                                                        
				                                                            
				                                                                | 17. | Bird TG, Dimitropoulou P, Turner RM, et al. Alpha-fetoprotein detection of hepatocellular carcinoma leads to a standardized analysis of dynamic AFP to improve screening based detection. PLoS One, 2016, 11(6): e0156801. doi: 10.1371/journal.pone.0156801. | 
				                                                        
				                                                            
				                                                                | 18. | Xie DY, Ren ZG, Zhou J, et al. 2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights. Hepatobiliary Surg Nutr, 2020, 9(4): 452-463. |